Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341014 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
A Phase 1 study of T-cell Lymphomas and Relapsed or Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT02341014 is a Phase 1 study of T-cell Lymphomas and Relapsed or Refractory that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants. The trial reports 6 study locations across 3 states.
The verdict
NCT02341014, a Phase 1 study of T-cell Lymphomas and Relapsed or Refractory, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Carfilzomib
- DRUG Romidepsin
Study Locations (6)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Mercy Medical Center - Rockville Centre
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Memoral Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-01-02 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341014
The ClinicalTrials.gov registry entry for NCT02341014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T-cell Lymphomas appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT02341014 reports 6 study locations spanning 3 distinct geographic areas - top geographies include New York, Nebraska, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02341014 about?
NCT02341014 is a clinical study titled "Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas". This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
What is the current status of trial NCT02341014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-01-02. Estimated completion is 2023-01-11.
What conditions does trial NCT02341014 study?
This clinical trial studies the following conditions: T-cell Lymphomas, Relapsed or Refractory.
What interventions are being tested in trial NCT02341014?
The interventions under investigation include: Lenalidomide (DRUG), Carfilzomib (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02341014?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02341014 being conducted?
This trial has 6 study locations across Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Lymphomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.